IP Library Granted Patent US 9,919,010
Granted Patent B2
US 9,919,010 · App. 12/990,086 · Granted Mar 20, 2018

Method for collecting functional cells in vivo with high efficiency

Inventors: Katsuto Tamai (Osaka, JP); Takehiko Yamazaki (Osaka, JP); Takenao Chino (Osaka, JP); Yasufumi Kaneda (Osaka, JP)
Assignees: GENOMIX CO., LTD.; OSAKA UNIVERSITY
A61K35/28C12N5/0663A61K2035/124
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,919,010
App. No.
12/990,086
Granted
Mar 20, 2018
Kind
B2
Abstract

Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

Claims (67)

1. A method for collecting bone-marrow-derived stem cells from a subject, wherein the method comprises:

(I) implanting for at least 12 hours a vessel that contains a substance of any of (a) to (j) below, completely under the skin in subcutaneous adipose of the subject, to induce stem cells present in the bone marrow of the subject to migrate to the vessel implanted in subcutaneous tissue, wherein, as a result of the presence of the substance, stem cells present in bone marrow of the subject enter the vessel implanted in subcutaneous adipose:

(a) an HMGB1 protein,

(b) a cell that secretes an HMGB1,

(c) an HMGB2 protein,

(d) a cell that secretes an HMGB2,

(e) an HMGB3 protein,

(f) a cell that secretes an HMGB3 protein,

(g) an S100A8 protein,

(h) a cell that secretes an S100A8 protein,

(i) an S100A9 protein,

and (j) a cell that secretes an S100A9 protein,

wherein the vessel is made from a material that is biologically hypoallergenic when implanted into the subject without any of (a) to (j), and wherein the vessel has one closed end to form an area therein to collect the bone-marrow-derived stem cells; and

(II) collecting bone-marrow-derived stem cells from the vessel.

2. The method according to claim 1 , wherein the bone-marrow-derived stem cells comprise bone marrow-derived mesenchymal stem cells, bone marrow stromal pluripotent stem cells, and/or bone marrow pluripotent stem cells.

3. The method according to claim 1 , wherein the step of collecting bone-marrow-derived stem cells is performed using vacuum aspiration.

4. The method according to claim 1 , wherein the vessel is implanted for at least one week.

5. The method according to claim 1 , wherein the vessel is implanted for at least 10 days.

6. The method according to claim 1 , wherein the vessel is implanted for at most two weeks.

7. The method according to claim 1 , wherein the vessel is implanted for 12 hours to two weeks.

8. The method according to claim 1 , wherein the vessel is implanted for one to two weeks.

9. The method according to claim 1 , wherein the vessel is implanted for 10 days to two weeks.

10. A method for collecting bone-marrow-derived stem cells from a subject, wherein the method comprises:

(I) implanting for at least 12 hours a vessel, that contains a substance of any of (a) to (j) below, completely under the skin in subcutaneous adipose of the subject, to induce stem cells present in the bone marrow of the subject to migrate to the vessel implanted in subcutaneous tissue, wherein, as a result of the presence of the substance, stem cells present in bone marrow of the subject enter the vessel implanted in subcutaneous adipose:

(a) an HMGB1 protein,

(b) a cell that secretes an HMGB1,

(c) an HMGB2 protein,

(d) a cell that secretes an HMGB2,

(e) an HMGB3 protein,

(f) a cell that secretes an HMGB3 protein,

(g) an S100A8 protein,

(h) a cell that secretes an S100A8 protein,

(i) an S100A9 protein, and

(j) a cell that secretes an S100A9 protein,

wherein the vessel is made from a material that is biologically hypoallergenic when implanted into the subject without any of (a) to (j), and wherein the vessel has one closed end to form an area therein to collect the bone-marrow-derived stem cells;

(II) removing the vessel to outside the body from under the skin in subcutaneous adipose of the subject; and

(III) collecting bone-marrow-derived stem cells from the vessel.

11. The method according to claim 10 , wherein the bone-marrow-derived stem cells comprise bone marrow-derived mesenchymal stem cells, bone marrow stromal pluripotent stem cells, and/or bone marrow pluripotent stem cells.

12. The method according to claim 10 , wherein the step of collecting bone-marrow-derived stem cells is performed using vacuum aspiration.

13. The method according to claim 10 , wherein the vessel is implanted for at least one week.

14. The method according to claim 10 , wherein the vessel is implanted for at least 10 days.

15. The method according to claim 10 , wherein the vessel is implanted for at most two weeks.

16. The method according to claim 10 , wherein the vessel is implanted for 12 hours to two weeks.

17. The method according to claim 10 , wherein the vessel is implanted for one to two weeks.

18. The method according to claim 10 , wherein the vessel is implanted for 10 days to two weeks.

19. A method for collecting bone-marrow-derived stem cells from a subject, wherein the method comprises:

(I) implanting for at least 12 hours a vessel that contains a substance of any of (a) to (j) below, completely under the skin in subcutaneous adipose of the subject, to induce stem cells present in the bone marrow of the subject to migrate to the vessel implanted in subcutaneous tissue, wherein, as a result of the presence of the substance, stem cells present in bone marrow of the subject enter the vessel implanted in subcutaneous adipose:

(a) an HMGB1 protein,

(b) a cell that secretes an HMGB1,

(c) an HMGB2 protein,

(d) a cell that secretes an HMGB2,

(e) an HMGB3 protein,

(f) a cell that secretes an HMGB3 protein,

(g) an S100A8 protein,

(h) a cell that secretes an S100A8 protein,

(i) an S100A9 protein, and

(j) a cell that secretes an S100A9 protein,

wherein the vessel is made from a material that is biologically hypoallergenic when implanted into the subject without any of (a) to (j), and wherein the vessel has one closed end to form an area therein to collect the bone-marrow-derived stem cells; and

(II) collecting bone-marrow-derived stem cells from the vessel, which is still under the skin in subcutaneous adipose of the subject.

20. The method according to claim 19 , wherein the bone-marrow-derived stem cells are a bone marrow-derived mesenchymal stem cell, a bone marrow stromal pluripotent stem cell, or a bone marrow pluripotent stem cell.

21. The method according to claim 19 , wherein the step of collecting bone-marrow-derived stem cells is performed using vacuum aspiration.

22. The method according to claim 19 , wherein the vessel is implanted for at least one week.

23. The method according to claim 19 , wherein the vessel is implanted for at least 10 days.

24. The method according to claim 19 , wherein the vessel is implanted for at most two weeks.

25. The method according to claim 19 , wherein the vessel is implanted for 12 hours to two weeks.

26. The method according to claim 19 , wherein the vessel is implanted for one to two weeks.

27. The method according to claim 19 , wherein the vessel is implanted for 10 days to two weeks.

Assignments (3)
CHANGE OF NAME Recorded Sep 18, 2018
From: GENOMIX CO., LTD.
To: STEMRIM INC.
Reel/Frame 047102/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2011
From: YAMAZAKI, TAKEHIKO; CHINO, TAKENAO
To: GENOMIX CO., LTD
Reel/Frame 025646/0992 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2011
From: TAMAI, KATSUTO; KANEDA, YASUFUMI
To: OSAKA UNIVERSITY
Reel/Frame 025647/0059 →
Priority Claims (1)
JP 2008-119355 · Apr 30, 2008 · national
Continuity (1)
Related Publication 20110104803A1 · May 5, 2011